



# Follicle-Stimulating Hormone (FSH) Assay Reagent Kit (CMIA) Package Insert

## INTENDED USE

The Follicle-Stimulating Hormone (FSH) Assay Reagent Kit (CMIA) is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of follicle-stimulating hormone (FSH) in human serum and plasma.

## PACKING SIZE

24 Device/Kit, 30 Device/Kit, 48 Device/Kit, 60 Device/Kit

## SUMMARY

Human follicle-stimulating hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. There are three other glycoprotein hormones, namely Thyroid Stimulating Hormone, Luteinizing Hormone (both produced by anterior pituitary gland) and Human Chorionic Gonadotropin (produced by the placenta) which are structurally similar. Each hormone has an alpha and beta subunit. The  $\alpha$  subunits of each hormone are similar while the  $\beta$  subunit is specific to each hormone. The  $\alpha$  subunits contain 92 amino acids while the  $\beta$  subunits vary with each hormone. The  $\beta$  subunit of both FSH and LH contain 115 amino acids, TSH 110 amino acids, and hCG 147 amino acids.

The FSH and LH hormones function differently in females and males. It is to be noted that in women the growth and maturation of the ovarian follicle is dependent on FSH, while in men both LH and FSH act on the testes.

## PRINCIPLE OF TEST

The FSH assay is a two-step immunoassay for the quantitative measurement of FSH in human serum and plasma using CMIA technology, with flexible assay protocols.

In the first step, sample and anti-FSH coated paramagnetic microparticles are combined. FSH present in the sample binds to the anti-FSH coated microparticles. After that, ALP-labeled anti-FSH conjugate is added to create a reaction mixture in the second step. Following the wash cycle, substrate is added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the amount of FSH in the sample and the RLUs detected by the system optics.

## REAGENTS

The device is pre-dispensed with buffer needed for single use.

The device is constituted with Buffers described below is the main reagent

| Object                 | Content  |
|------------------------|--|
| Micro-particles Buffer | Anti-FSH (mouse, monoclonal) coated Micro-particles in TRIS buffer with protein (bovine) stabilizer. Minimum concentration: 0.1% solid. Preservative: ProClin-300. |
| Conjugate Buffer       | Anti-FSH (mouse, monoclonal) alkaline phosphatase (ALP) labeled conjugate in TRIS buffer with protein (bovine) stabilizer. Preservative: ProClin-300.              |
| Wash Buffer            | TRIS buffer with surfactant. Preservative: ProClin-300.  |
| Substrate Buffer       | AMPPD, Enhancer, Surfactant, ProClin-300.  |

## Reagent Handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

## MATERIALS PROVIDED

- FSH Test Device
- Product Insert
- Calibration Solution (optional)
- Control Solution (optional)

## MATERIALS REQUIRED BUT NOT PROVIDED

- Analyzer

## STORAGE AND STABILITY

- Store at 2-8°C and avoid light.
- Do not freeze.
- Store the reagent kit upright prior to use.
- Expiration date: up to the stated expiration date.

Note: The FSH Assay Reagent Kit must be stored at 2-8°C in an upright position, and must be used immediately after removal from 2-8°C storage or the device was opened. Unused reagents should be put back into the kit in time.

## SPECIMEN COLLECTION AND STORAGE

### Specimen Types

Validated specimen types to be used with this assay:

| Specimen Types | Collection Tubes                                 |
|----------------|--|
| Human serum    | Serum<br>Serum separator tubes                   |
|                | Sodium heparin                                   |
| Human plasma   | Lithium heparin<br>Potassium EDTA<br>Sodium EDTA |

Other anticoagulants have not been validated for use with this assay.

The instrument does not provide the capability to verify specimen type. It is the responsibility of the operator to verify that the correct specimen types are used in the assay.

### Specimen Conditions

- Do not use specimens with the following conditions:  
heat-inactivated  
pooled  
grossly hemolyzed  
obvious microbial contamination
- For optimal results, serum and plasma specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens especially those from patients receiving anticoagulant or thrombolytic therapy may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

### Preparation for Analysis

- Follow the tube manufacturer's processing instructions for specimen collection tubes.
- Specimens must be mixed THOROUGHLY after thawing, by LOW speed vortex, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results.
- Inspect all specimens for bubbles. Remove bubbles with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.

### Specimen Storage

| Specimen Type | Storage Temperature | Maximum Storage Time |
|---------------|---------------------|----------------------|
| Serum/Plasma  | 2-8°C               | 6 days               |

- If testing will be delayed more than 24 hours, remove serum or plasma from the clot, serum separator or red blood cells.
- If testing will be delayed more than 6 days, specimens should be frozen at -10°C or colder.
- Specimens stored frozen at -10°C or colder for 3 months showed no performance difference.
- Avoid more than 3 freeze/thaw cycles.
- Before shipping specimens, it is recommended that specimens be removed from the clot, red blood cells, or separator gel.
- When shipping specimens, package and label specimens in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances.
- Specimens may be shipped ambient, at 2-8°C (wet ice), or frozen (dry ice). Do not exceed the storage time limitations listed above.

## INSTRUMENT

The FSH Test Device is designed for use on the REALY Analyzer System.

## TEST PROCEDURE

### Assay Procedure

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer specific assay instructions. Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the digit sequence of numbers. Bring the cooled reagents to approx. 20°C and place on the reagent disk of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents.

For this test device, the transfer volume of specimens, calibrators or controls into the sample hole is 70  $\mu$ L. (No less than 70  $\mu$ L.)

Reagent strips should be left at room temperature between 20 and 25 °C for more than 30 minutes before use and kept away from light.

In order to avoid the magnetic beads adsorbed on the side wall and top due to the upside down and side placement of the reagent strip during transportation, the reagent strip should be mixed by shaking and mixing before use. The reagent strip should be mixed upside down for about 30 seconds, and then the reagent strip should be mixed upward for about 30 seconds. The reagent strip was then gently shaken so that the magnetic beads fell completely to the bottom of the strip.

### Calibration

Every Test Device has a barcode label containing specific information for calibration of the particular reagent lot. The pre-defined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed before new lot of device is used.

Renewed calibration is recommended as follows:

- After 90 days (when using the same reagent lot on the analyzer);
- As required: e.g. quality control findings outside the defined limits.

Note: Refer to Instruction of Analyzer for the procedure of calibration.

### Quality Control

For quality control, please use Control of REALY or Control Universal.

In addition, other suitable control material can be used. Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

### Specimen Dilution Procedures

Specimens with an FSH concentration greater than 200 mIU/mL will be flagged as ">>200 mIU/mL" and may be diluted using Manual Dilution Procedure. Use the 1:2 dilutions is recommended. The operator must enter the dilution factor in the Patient or Control order screen. The system will use this dilution factor to automatically calculate the concentration of the sample before dilution.

## EXPECTED VALUES

Reference value:

|                   |                   |
|-------------------|-------------------|
| Males:            | 1.5-12.4 mIU/mL   |
| Females           |                   |
| Follicular phase: | 3.5-12.6 mIU/mL   |
| Ovulation phase:  | 4.7-21.5 mIU/mL   |
| Luteal phase:     | 1.7-7.7 mIU/mL    |
| Post-menopause:   | 25.8-134.8 mIU/mL |

Results may differ between laboratories due to variations in population and test method. If necessary, advice each laboratory set up your own reference range.

## INTERPRETATION OF RESULTS

As interpret the results, the patient's overall clinical situation, including symptoms, medical history and other related data, should be referred to.

## LIMITATIONS

- If the FSH results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
- For diagnostic purposes, results should be used in conjunction with other data; e.g., symptoms, results of other tests, clinical impressions, etc.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits such as REALY FSH that employ mouse monoclonal antibodies.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed. Additional information may be required for diagnosis.
- Although the REALY FSH assay is specifically designed to minimize the effects of HAMA and heterophilic antibodies, assay results that are not consistent with other clinical observations may require additional information for diagnosis.

## PERFORMANCE CHARACTERISTICS

### Linearity

The linearity of FSH Reagent Kit was determined by use FSH calibrator to prepare 6 different specimens, measuring all these specimens follow the test instruction and then do linear fitting, the results show that the linear correlation coefficient (r) was not less than 0.9900.

### Precision/Reproducibility

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum. Repeatedly measured 20 times, calculating the coefficient of variation.

| Intra-assay Precision |               |             |       |
|-----------------------|---------------|-------------|-------|
| Control               | Mean (mIU/mL) | SD (mIU/mL) | CV    |
| Level 1               | 7.41          | 0.43        | 5.80% |
| Level 2               | 48.57         | 1.71        | 3.52% |
| Level 3               | 138.12        | 4.73        | 3.42% |

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 30 times, calculating the coefficient of variation.

| Inter-assay Precision |               |             |       |
|-----------------------|---------------|-------------|-------|
| Control               | Mean (mIU/mL) | SD (mIU/mL) | CV    |
| Level 1               | 7.37          | 0.59        | 8.01% |
| Level 2               | 47.31         | 2.56        | 5.41% |
| Level 3               | 136.63        | 8.32        | 6.09% |

### Analytical Sensitivity

The analytical sensitivity is defined as the concentration of FSH equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The analytical sensitivity is typically less than 0.2 mIU/mL.

### Analytical Specificity

The specificity of the FSH assay system was assessed by measuring the apparent

response of the assay to various potentially cross-reactive analytes.

| Compound | Concentration | Cross-reactivity |
|----------|---------------|------------------|
| hCG      | 20000 mIU/mL  | < 0.05%          |
| LH       | 200 mIU/mL    | < 0.05%          |
| TSH      | 20 µIU/mL     | < 0.05%          |

### Interference

The following compounds in both low-level specimen and high-level specimen show no cross-reactivity when tested with the FSH Assay Reagent Kit at a concentration below:

| Compound      | Concentration |
|---------------|---------------|
| Bilirubin     | 10 mg/dL      |
| Hemoglobin    | 500 mg/dL     |
| Triglycerides | 1000 mg/dL    |

### Method Comparison

The comparison between the FSH Assay Reagent Kit (y) and a commercially available FSH test kit (x), using clinical samples gave the following correlations (mIU/mL):

Linear regression

$$y=0.9877x+1.0757$$

$$r=0.9758$$

Number of samples measured: 87

The sample concentrations were between about 1.0 – 200 mIU/mL.

## WARNINGS AND PRECAUTIONS

- For *In Vitro* Diagnostic Use.
- Do not use expired or clearly damaged kits.
- Operating according to the steps described, can make the risk of daily handling patients' samples and blood products into a minimum, however, no matter what the source of the products, handling mode or the previous proof, these potentially infectious substances were used shall be in accordance with the unified considerations and Good Laboratory Practice (GLP).
- Proper disinfectant should be used to eliminate pollution.
- Follow local rules and regulations to keep and dispose of these items and containers for these items.
- The ProClin-300 is a potential skin sensitizer. Avoid dumping or splashing this reagent on your skin and clothing. In case of contact with this reagent, wash thoroughly with soap and water.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- The reagents should be kept away from light, and unused reagents should be put back into the kit in time and be careful to avoid light.

## BIBLIOGRAPHY

1. Vaitukaitis JL and Ross GT. Antigenic similarities among the human glycoprotein hormones and their subunits Gonadotropins, 1972; Edited by Saxena BB, Gandy HM and Beling CG. New York, NY: John Wiley and Sons,435-443.
2. Pierce JG and Parsons TF. Glycoprotein hormones structure and function. Annual Review of Biochemistry.190. 465-495.
3. South SA Yankov VI and Evans WS. Normal reproductive neuroendocrinology in the female. In Endocrinology and Metabolism Clinics of North America. Edited by Veldhuis JD, Philadelphia PA: WB Saunders Co.. 1993;22: 1-28.
4. Adashi EY. The ovarian life cycle. In Reproductive Endocrinology. Edited by Yen SSC and Jaffe RB. Philadelphia, PA WB Saunders Co., 1992;22: 1-28.
5. Yen SSC. The human menstrual cycle. Neuroendocrine regulation. In Reproductive Endocrinology. Edited by Yen SSC and Jaffe RB. Philadelphia, PA: WB Saunders Co. 1991;273-308.
6. Richardson SJ. The biological basis of menopause. In: Baller's Clinical Endocrinology and Metabolism, 1993;7:1-16.
7. Reyes Fuentes A and Veldhuis JD. Neuroendocrine physiology of the normal male gonadal axis. In: Endocrinology and Metabolism Clinics of North America. Edited by Veldhuis JD. Philadelphia, PA: WB Saunders Co. 1993. 22:93-124.
8. Car BR. Disorders of the ovary and female reproductive tract. In: Williams Textbook of Endocrinology, 8th edition. Edited by Wilson JD and Foster DW. Philadelphia, PA: WB Saunders Co, 1992; 733-798.

9. Hall JE. Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis. In: Endocrinology and Metabolism Clinics of North America, Neuroendocrinology I. Edited by Veldhuis JD. Philadelphia, PA: WB Saunders Co, 1993; 75-92.

## SYMBOLS


| Symbol | Meaning                            | Symbol | Meaning   |
|--------|------------------------------------|--------|---|
|        | In vitro diagnostic medical device |        | Storage temperature limit   |
|        | Manufacturer                       |        | Authorized representative in the European Community /European Union     |
|        | Date of Manufacture                |        | Use-by date   |
|        | Do not re-use                      |        | Consult instructions for use or consult electronic instructions for use |
|        | Batch code                         |        | Do not use if package is damaged and consult instructions for use       |
|        | Catalogue number                   |        | Contains sufficient for <n> tests                                       |



### Hangzhou Realy Tech Co., Ltd.

#2 Building, No. 763, Yuansha Village, Xinjie Street, Xiaoshan District, 311200 Hangzhou City, Zhejiang Province, PEOPLE'S REPUBLIC OF CHINA

Website: [www.realytech.com](http://www.realytech.com)



### Luxus Lebenswelt GmbH

Kochstr.1,47877, Willich, Germany

Number:1100051803

Version:1.6

Effective Date:2023-08-10